Tofacitinib

BreastfeedingGeriatricPediatric

FDA APPROVAL DATE: 11/06/2012

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Azathioprine, Biologic disease-modifying antirheumatics, Cyclosporine, CYP3A4 inhibitors, Fluconazole, Ketoconazole, Live vaccines, Potent immunosuppressives, Rifampin, Strong CYP inducers, Strong CYP2C19 inhibitors, Tacrolimus

PREGNANCY CATEGORY: C

SERIOUS INFECTIONS AND MALIGNANCY

See full prescribing information for complete boxed warning.

Our database has 62 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
HEMATOLOGIC
LOCAL
OTHER


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric